Circulating PRCP in STEMI Patients Undergoing Primary PCI
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Purpose: The purpose of this study is to evaluate the impact of acute ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (PCI) on circulating prolylcarboxypeptidase (PRCP) level and activity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy subjects, consecutive patients with unstable angina, and those undergoing primary PCI for STEMI
Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes;
Age ≥18 years;
Informed consent from subject or next of kin.
Cardiac surgery planed in the 6 months;
Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation);
Renal or hepatic failure;
Malignancy, HIV, or central nervous system disorder;
Cardiopulmonary resuscitation >15 min and compromised level of consciousness;
Current participation in any research study involving investigational drugs or devices;